Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 12/20 | 0.64 |
| ▸ | HRH1 | P35367 | 2/20 | 0.58 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.57 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.57 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22722179 | 0.99 | REN (0.65) | RENHRH1ERAP2ERAP1LNPEP | |
| SCHEMBL18862235 | 0.99 | REN (0.65) | RENHRH1ERAP2ERAP1LNPEP | |
| SCHEMBL18862365 | 0.97 | REN (0.67) | RENHRH1ERAP2ERAP1LNPEP | |
| SCHEMBL18862259 | 0.92 | REN (0.57) | RENHRH1ERAP2ERAP1LNPEP | |
| SCHEMBL18862249 | 0.90 | REN (0.59) | RENHRH1ERAP2ERAP1LNPEP | |
| SCHEMBL18862444 | 0.90 | REN (0.55) | RENHRH1ERAP2ERAP1LNPEP | |
| SCHEMBL18862059 | 0.90 | REN (0.54) | RENHRH1ERAP2ERAP1LNPEP | |
| SCHEMBL18862332 | 0.89 | REN (0.69) | RENHRH1ERAP2ERAP1LNPEP | |
| SCHEMBL18862086 | 0.87 | REN (0.51) | RENHRH1ERAP2ERAP1LNPEP | |
| SCHEMBL18862087 | 0.86 | HRH1 (0.51) | RENHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139892-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA TO A CELL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-13 | — | — | US | disclosed |
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| WO-2017083368-A9 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | PFIZER INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| US-20170137801-A1 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-18 | — | — | US | disclosed |
| WO-2017083368-A1 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | PFIZER INC. (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | ASGR1, LDLR, HAVCR2 | REN 2795/4885HRH1 2717/4885ERAP2 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.